

United States Patent and Trademark Office

UNITED STATES DAYASTERDY DY COMMERCE United States Patent and Trisdensia Colleg Address ConditionNER OF PATENTS AND TRADESIANCE Windrages, D.C. 2023

			• •	
APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/692, 07 7	10/19/2000	O I P	13105	ទ ទេ
William D Schmidt Kalow & Springut LLP 488 Madison Avenue 19th Fl		MAR 2 5 2003 46	EXAMINER	
			Johannsen, Diana B	
New York, NY	10022		ART UNIT	PAPER NUMBER
		THO PHARM OF IC	1614 DATE MAILED: 11/20/2002	14

Please find below and/or attached an Office communication concerning this application or proceeding.

PTO-90C (Rev. 07-01)

pplication/Control Number: 09/692,077

Page 2

Art Unit: 1634

The communication filed August 19, 2002 is not fully responsive to the Office communication mailed April 19, 2002 for the reason(s) set forth on the attached Notice To Comply With The Sequence Rules. Specifically, it is noted that Sequence Listing is incomplete, as, e.g., sequences recited in Figures 1 and 2 are not included therein. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.

Since the above-mentioned reply appears to be a bona fide attempt to comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825), applicant is given a TIME PERIOD of ONE (1) MONTH from the mailing date of this communication within which to correct the deficiency so as to comply with the sequence rules (37 CFR 1.821 - 1.825) in order to avoid abandonment of the application under 37 CFR 1.821(g). EXTENSIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER 37 CFR 1.136(a).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Diana Johannsen whose telephone number is (703)305-0761. The examiner can normally be reached on Monday-Friday from 7:30 a.m. to 4:00 p.m.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, W. Gary Jones, can be reached at (703) 308-1152. The fax phone number for the Technology Center where this application or proceeding is assigned is (703) 305-3014 or 305-4242.

MAR-20-2003 14:02

KALOW & SPRINGUT LLP

212 813 9600

P.04/05

Application/Control Number: 09/692,077

Page 3

Art Unit: 1634

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

Diana Johannsen

November 18, 2002

lication No.: <u>09/692.077</u>

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

KALOWA SPRINGUT LLP

MAR 2 5 2003 &

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

X	1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
	 This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1,821(e),
	and the state of t
X	7. Other: Incomplete Sequence Listing
لسما	
لسما	7. Other: incomplete Sequence Listing
Ap	7. Other: incomplete Sequence Listing plicant Must Provide:
Ap X	7. Other: <u>Incomplete Sequence Listing</u> plicant Must Provide: An initial or <u>substitute</u> computer readable form (CRF) copy of the "Sequence Listing". An initial or <u>substitute</u> paper copy of the "Sequence Listing", as well as an amendment directing its entry
Ap X X	7. Other: Incomplete Sequence Listing plicant Must Provide: An initial or substitute computer readable form (CRF) copy of the "Sequence Listing". An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification. A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or
Ap X X For For For	7. Other: Incomplete Sequence Listing plicant Must Provide: An initial or substitute computer readable form (CRF) copy of the "Sequence Listing". An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification. A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY

Docket No.: 10738-43 **CERTIFICATE OF MAILING**

I hereby certify that this paper is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Box Sequence Listing, P.O. Box 2327, Arlington, VA 22202 on March 20, 2003.

eW. Moore

UNITED STATES PATENT AND TRADEMARK OFFICE

pplicant:

Kersten M. Small et al

Paper No.:

Serial No.:

09/692,077

Filed:

Group Art Unit: 1634

October 19, 2000

Examiner: Johannsen, Diana

For:

Alpha-2B-Adrenergic Receptor Polymorphisms

REQUEST FOR AUTHORIZATION TO AMEND THE DRAWINGS

Box Sequence Listing P.O. Box 2327 Arlington, VA 22202

Dear Sir:

Applicants request authorization to amend the drawings as shown in the attached Figures. Applicants request authorization to amend the drawings to incorporate Sequence Identification Numbers for the Sequence Listings disclosed in Figures 1 and 2, as shown in red. In addition, Applicant requests authorization to amend the drawings to delete non essential matter in Figure 2, as shown in red.

No new matter is believed to be involved, and therefore approval of the amended drawings is respectfully requested. Please charge any fees required, and credit any overpayment, to Deposit Account No. 04-1133.

Respectfully submitted,

Denise M. Everett

Registration No. 47,552 Attorney for Applicant

DINSMORE & SHOHL LLP

1900 Chemed Center 255 East Fifth Street Cincinnati, Ohio 45202

(513) 977-8787

882005v1